Daclatasvir 60 Tablets

Product Details:

Drug Type Generic Drugs
Ingredients DACLATSVIR 60
Physical Form Tablets
Function Anti-Viral
Recommended For Chronic hepatitis C virus (HCV) infection
Dosage Missed Dose Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose. Overdose Seek emergency medical treatment or contact the doctor in case of an overdose.
Suitable For Adults
Share Your Product:

68.27-75.01 USD ($)/Bottle

Get a Price/Quote

Request To Call Back Send Inquiry

Daclatasvir 60 Tablets Price And Quantity

Minimum Order Quantity 3 Bottle
Price 68.27-75.01 USD ($)/Bottle

Daclatasvir 60 Tablets Product Specifications

Storage Instructions ROOM TEMP. 10 -30 C
Physical Form Tablets
Drug Type Generic Drugs
Recommended For Chronic hepatitis C virus (HCV) infection
Function Anti-Viral
Dosage Missed Dose Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose. Overdose Seek emergency medical treatment or contact the doctor in case of an overdose.
Ingredients DACLATSVIR 60
Quantity 50 Unit
Suitable For Adults

Daclatasvir 60 Tablets Trade Information

Payment Terms Cash in Advance (CID)
Supply Ability 50 Bottle Per Week
Delivery Time 3 Week
Packaging Details 1*28S/BOTT
Main Export Market(s) Australia Eastern Europe Central America Middle East South America Asia Western Europe North America Africa
Main Domestic Market All India

Product Description

Other Products in 'Pharmaceutical Tablets' category

AMOXAPINE TAB Price : 13.66-16.39 USD ($)/Box Minimum Order Quantity : 5 Physical Form : Tablets Storage Instructions : ROOM TEMP. 10 30 C Suitable For : Adults Quantity : 100 Boxes Ingredients : AMOXAPINE Function : Other Dosage : Missed Dose Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose. Overdose Seek emergency medical treatment or contact the doctor in case of an overdose. Recommended For : DEPRESSION Drug Type : Generic Drugs

Send Inquiry

TENOFOVIR 300 Price : 12.98-15.71 USD ($)/Bottle Minimum Order Quantity : 5 Physical Form : Tablets Storage Instructions : ROOM TEMP. 10 30 C Suitable For : Adults Quantity : 10 Unit Ingredients : TENOFOVIR 300 Function : AntiViral Dosage : Recommended Dose in Adults: For the treatment of HIV1 or chronic hepatitis B : The dose is one 300mg Tenofovir Disoproxil Fumarate 300mg Tablets once daily taken orally, without regard to food. In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown. Recommended For : HIV infection Chronic hepatitis B virus (HBV) infection Drug Type : Specific Drug

Send Inquiry

Ethinyl Estradiol+Cyproterone Tab Price : 4.43-4.80 USD ($)/Box Minimum Order Quantity : 5 Physical Form : Tablets Storage Instructions : ROOM TEMP. 10 30 C Suitable For : Women Quantity : 50 Boxes Ingredients : CYPROTERONE + ETHINYL ESTRADIOL Function : Other Dosage : Missed Dose Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose. Overdose Seek emergency medical treatment or contact the doctor in case of an overdose. Recommended For : Polycystic ovarian syndrome (PCOS) Drug Type : Generic Drugs

Send Inquiry

Abiraterone Acetate 250mg Price : 259.59-273.26 USD ($)/Bottle Minimum Order Quantity : 3 Physical Form : Tablets Storage Instructions : ROOM TEMP. 10 30 C Suitable For : Adults, Aged Person Quantity : 5 Boxes Ingredients : ABIRATERONE 250 Function : Cancer Treatment Dosage : Prostate Cancer Metastatic castrationresistant prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic castrationresistant prostate cancer (CRPC) 1000 mg (two 500mg tablets or four 250mg tablets) PO qDay with prednisone 5 mg PO q12hr Yonsa Indicated in combination with methylprednisolone for the treatment of patients with metastatic CRPC 500 mg (four 125mg tablets) PO qDay in combination with methylprednisolone 4 mg PO BID Metastatic highrisk castrationsensitive prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic highrisk castrationsensitive prostate cancer (CSPC) 1000 mg (two 500mg tablets or four 250mg tablets) PO qDay with prednisone 5 mg PO q12hr Dosage Modifications Strong CYP3A4 inducers Coadministration with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Avoid if possible; if strong CYP3A4 inducer must be administered, increase abiraterone dosage frequency of abiraterone Reduce dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued Yonsa Increase from 500 mg qDay to 500 mg BID Zytiga Increase from 1000 mg qDay to 1000 mg BID Hepatic impairment (Zytiga) Baseline LFTs Mild (ChildPugh A): No dosage adjustment necessary Moderate (ChildPugh B): Reduce starting dose to 250 mg PO qDay; monitor ALT, AST, and bilirubin prior to start of treatment, qWeek for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone and do not retreat patients Severe (ChildPugh C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN: Interrupt treatment; reinitiate at reduced dose of 750 mg PO qDay following return of LFTs to baseline or to AST/ALT ≤2.5x ULN and total bilirubin ≤1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs at 750 mg/day, may restart at 500 mg/day (after LFTs decrease as above) If hepatoxicity recurs at reduced dose of 500 mg/day, discontinue treatment Permanently discontinue treatment for patients who develop a concurrent elevation of ALT >3x ULN and total bilirubin >2x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation Hepatic impairment (Yonsa) Baseline Moderate (ChildPugh Class B): Reduce 125 mg PO qDay; monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment: Discontinue treatment and do not retreat patients with abiraterone Severe (ChildPugh Class C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN): Interrupt treatment; restart at a reduced dose of 375 mg qDay following return of liver function tests to the patient’s baseline or to AST and ALT ≤2.5x ULN and total bilirubin ≤1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs on 375 mg/day, may be restart aeduced dose of 250 mg/day (after LFTs decrease as above) I Drug Type : Specific Drug

Send Inquiry

SEND INQUIRY CALL ME FREE